Sosnay, Patrick R

Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial

Heijerman, H. G. M., McKone, E. F., Downey, D. G., Van Braeckel, E., Rowe, S. M., Tullis, E., Mall, M. A., Welter, J. J., Ramsey, B. W., McKee, C. M., et al. (2019) · The Lancet

Cystic Fibrosis Research AdvancesPharmacogenetics and Drug Metabolism

Cited by 1,414

Diagnosis of Cystic Fibrosis: Consensus Guidelines from the Cystic Fibrosis Foundation

Farrell, P. M., White, T. B., Ren, C. L., Hempstead, S. E., Accurso, F., Derichs, N., Howenstine, M., McColley, S. A., Rock, M., Rosenfeld, M., et al. (2017) · The Journal of Pediatrics

Cystic Fibrosis Research AdvancesGenomics and Rare Diseases

Cited by 953

Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene

Sosnay, P. R., Siklosi, K. R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., Ramalho, A. S., Amaral, M. D., Dorfman, R., Zielenski, J., et al. (2013) · Nature Genetics

Cystic Fibrosis Research AdvancesGenomics and Rare Diseases

Cited by 630

Sweat test for cystic fibrosis: Wearable sweat sensor vs. standard laboratory test

Choi, D.-H., Thaxton, A., Jeong, I. C., Kim, K., Sosnay, P. R., Cutting, G. R., & Searson, P. C. (2018) · Journal of Cystic Fibrosis

Cystic Fibrosis Research AdvancesAnalytical Chemistry and Sensors

Cited by 80